CD8A and neoplasm: Compared with recognized signatures (or genes) including Merck18, TIDE score, microsatellite instability (MSI) score, tumor mutation burden (TMB), CD274, CD8, IFNG, T clonality, and B clonality, the IIRS showed robust ability in predicting the response to immunotherapies in patients with different cancers.